S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.30
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
Free Stock Analysis Report: See The True Value of Any Stock (Ad)pixel
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
Free Stock Analysis Report: Take Control of Your Stocks (Ad)pixel
Which Gold Stocks Can Help You Hedge Bank Exposure?
Enphase Energy is Still a Buy for Long-Term Growth Investors
NASDAQ:ALKS

Alkermes - ALKS Stock Forecast, Price & News

$26.03
-0.65 (-2.44%)
(As of 03/17/2023 06:55 PM ET)
Add
Compare
Today's Range
$25.98
$26.66
50-Day Range
$26.03
$29.02
52-Week Range
$21.75
$32.79
Volume
2.06 million shs
Average Volume
1.31 million shs
Market Capitalization
$4.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.11

Alkermes MarketRank™ Forecast

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
15.7% Upside
$30.11 Price Target
Short Interest
Bearish
5.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.22
Upright™ Environmental Score
News Sentiment
0.36mentions of Alkermes in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to $1.02 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

Medical Sector

811th out of 983 stocks

Pharmaceutical Preparations Industry

387th out of 480 stocks


ALKS stock logo

About Alkermes (NASDAQ:ALKS) Stock

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Stock News Headlines

StockNews.com Begins Coverage on Alkermes (NASDAQ:ALKS)
Alkermes (ALKS) Stock Up 15% in Six Months: Here's Why
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Alkermes to Participate in the Stifel 2023 CNS Days
Alkermes Full Year 2022 Earnings: Beats Expectations
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
Alkermes Testing Schizophrenia Drug
See More Headlines
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Company Calendar

Last Earnings
2/16/2023
Today
3/20/2023
Next Earnings (Estimated)
4/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,280
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$30.11
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+15.7%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$-158,270,000.00
Pretax Margin
-15.05%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$0.25 per share
Book Value
$6.35 per share

Miscellaneous

Free Float
156,564,000
Market Cap
$4.28 billion
Optionable
Optionable
Beta
0.60

Social Links


Key Executives

  • Richard F. PopsRichard F. Pops
    Chairman & Chief Executive Officer
  • Blair C. JacksonBlair C. Jackson
    Chief Operating Officer & Executive Vice President
  • Iain Michael BrownIain Michael Brown
    Chief Financial Officer & Senior Vice President
  • Thomas Harvey
    Chief Information Officer & Senior VP-IT
  • Kanchan Relwani
    Senior Vice President-Medical Affairs













ALKS Stock - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALKS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View ALKS analyst ratings
or view top-rated stocks.

What is Alkermes' stock price forecast for 2023?

8 Wall Street research analysts have issued 1 year price objectives for Alkermes' stock. Their ALKS share price forecasts range from $25.00 to $36.00. On average, they expect the company's share price to reach $30.11 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price.
View analysts price targets for ALKS
or view top-rated stocks among Wall Street analysts.

How have ALKS shares performed in 2023?

Alkermes' stock was trading at $26.13 at the beginning of 2023. Since then, ALKS shares have decreased by 0.4% and is now trading at $26.03.
View the best growth stocks for 2023 here
.

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our ALKS earnings forecast
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) announced its earnings results on Thursday, February, 16th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.05 by $0.09. The firm earned $304.70 million during the quarter, compared to analysts' expectations of $289.80 million. Alkermes had a negative net margin of 14.23% and a negative trailing twelve-month return on equity of 3.32%. Alkermes's quarterly revenue was down 6.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.13 earnings per share.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2023 earnings guidance on Monday, February, 20th. The company provided earnings per share guidance of 0-$0.23 for the period, compared to the consensus estimate of $0.26. The company issued revenue guidance of $1.13 billion-$1.25 billion, compared to the consensus revenue estimate of $1.17 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sarissa Capital Management LP (5.46%), Renaissance Technologies LLC (3.44%), Hardman Johnston Global Advisors LLC (3.38%), Cibc World Markets Corp (3.09%), Millennium Management LLC (2.09%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Blair Curtis Jackson, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends
.

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $26.03.

How much money does Alkermes make?

Alkermes (NASDAQ:ALKS) has a market capitalization of $4.28 billion and generates $1.11 billion in revenue each year. The company earns $-158,270,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis.

How many employees does Alkermes have?

The company employs 2,280 workers across the globe.

Does Alkermes have any subsidiaries?
The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More
How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The official website for the company is www.alkermes.com. The company can be reached via phone at (531) 772-8000, via email at investor_relations@alkermes.com, or via fax at 781-890-0524.

This page (NASDAQ:ALKS) was last updated on 3/20/2023 by MarketBeat.com Staff